{"altmetric_id":20530480,"counts":{"readers":{"mendeley":0,"citeulike":0,"connotea":0},"total":{"posts_count":1},"news":{"unique_users_count":1,"unique_users":["seeking_alpha"],"posts_count":1}},"citation":{"altmetric_jid":"588f1b3f7ac79ee9d1496f63","authors":["Fumiko Axelrod","Hyun-Bae Jie","Erin Mayes","Jorge Monteon","Minu Srivastava","Rui Yun","Inkyung Angie Park","Austin Gurney"],"doi":"10.1158\/2326-6074.cricimteatiaacr15-a058","first_seen_on":"2017-05-26T08:14:15+00:00","issns":["2326-6066","2326-6074"],"journal":"Cancer Immunology Research","last_mentioned_on":1495740864,"links":["http:\/\/cancerimmunolres.aacrjournals.org\/content\/4\/1_Supplement\/A058"],"pubdate":"2016-01-01T00:00:00+00:00","publisher":"American Association for Cancer Research","title":"Abstract A058: GITRL-Fc, an immunotherapeutic agent that stimulates T-cell-mediated antitumor immune response","type":"article"},"altmetric_score":{"score":7,"score_history":{"1y":7,"6m":7,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":8266357,"mean":6.977935429341,"rank":1202355,"this_scored_higher_than_pct":84,"this_scored_higher_than":6989573,"rank_type":"exact","sample_size":8266357,"percentile":84},"similar_age_3m":{"total_number_of_other_articles":238029,"mean":12.092241694254,"rank":48904,"this_scored_higher_than_pct":78,"this_scored_higher_than":187323,"rank_type":"exact","sample_size":238029,"percentile":78},"this_journal":{"total_number_of_other_articles":469,"mean":6.6425085470085,"rank":70,"this_scored_higher_than_pct":83,"this_scored_higher_than":393,"rank_type":"exact","sample_size":469,"percentile":83},"similar_age_this_journal_3m":{"total_number_of_other_articles":20,"mean":3.0263157894737,"rank":2,"this_scored_higher_than_pct":90,"this_scored_higher_than":18,"rank_type":"exact","sample_size":20,"percentile":90}}},"demographics":[],"posts":{"news":[{"title":"Is OncoMed A Contrarian Buy?","url":"http:\/\/ct.moreover.com\/?a=30692434284&p=1pl&v=1&x=MyVcFqMzgnZE6buwhBzGtg","license":"public","citation_ids":[4562417,20530479,16923640,20530480,1828056],"posted_on":"2017-05-25T19:34:24+00:00","summary":"Summary OncoMed Pharmaceuticals has discontinued its early clinical studies of its hopeful candidate demcizumab, cutting its partnership potential with Celgene.","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}}]}}